Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Anticipated to Record Steady Gains, Advancing to $29.13 Billion by 2030
Uncover key drivers, emerging technologies, and competitive movements shaping the chronic obstructive pulmonary disease (copd) treatment market from 2026–2035 with trusted insights from The Business Research Company
What is the expected shift in the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market’s size between 2026 and 2030?
The market size for chronic obstructive pulmonary disease (COPD) treatment has experienced robust expansion in recent years. This market is projected to expand from $21.73 billion in 2025 to $22.9 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.4%. Historically, this growth has been driven by factors such as a high prevalence of smoking, an expanding aging population, elevated levels of air pollution, increased exposure to occupational dust, and enhanced awareness regarding COPD.
The chronic obstructive pulmonary disease (copd) treatment market size is anticipated to experience significant expansion in the coming years. It is projected to grow to $29.13 billion in 2030, achieving a compound annual growth rate (CAGR) of 6.2%. This growth over the forecast period can be attributed to the increasing adoption of combination therapies, the expansion of homecare treatment models, rising healthcare expenditure, an increase in copd diagnosis rates, and innovations in inhalation drug delivery. Key developments expected during this outlook period encompass the rising adoption of triple combination inhaler therapies, a growing shift towards home-based copd management, an increased focus on early diagnosis and disease screening, the proliferation of generic and cost-effective copd drugs, and a higher utilization of non-pharmacological pulmonary rehabilitation.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10054&type=smp
Which Drivers Are Shaping Strategic Decisions In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
The rising incidence of smoking is anticipated to boost the expansion of the chronic obstructive pulmonary disease (COPD) treatment market moving ahead. Smoking is defined as the act of inhaling smoke, usually from combustion materials like tobacco, via the mouth. For individuals who smoke, COPD treatment is favored due to its benefits, including better respiration, a higher quality of life, fewer severe episodes, enhanced physical activity tolerance, extended lifespan, and better psychological well-being. A relevant example is from July 2023, when the World Health Organization, an intergovernmental body situated in Switzerland, reported that tobacco claims over 8 million lives annually, a figure that includes 1.3 million non-smokers exposed to second-hand smoke. Consequently, the expanding occurrence of smoking is a key factor stimulating the growth of the chronic obstructive pulmonary disease (COPD) treatment market.
What Segment Categories Are Covered In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
The chronic obstructive pulmonary disease (copd) treatment market covered in this report is segmented –
1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes
2) By Type: Chronic Bronchitis, Emphysema
3) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Combination Therapy: Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS), Long-Acting Muscarinic Antagonists (LAMA) + LABA, Triple Therapy (LAMA + LABA + ICS)
2) By Bronchodilators: Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA)
3) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Injectable Corticosteroids
4) By Phosphodiesterase Type 4 Inhibitor: Roflumilast, Other PDE4 Inhibitors
5) By Mucokinetics: Expectorants, Mucolytics
6) By Other Drug Classes: Antibiotics, Antivirals, Antifungal Agents
What Trends Are Reshaping The Dynamics Of The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Major companies operating in the chronic obstructive pulmonary disease (COPD) treatment market are prioritizing innovative products, such as Vilfuro-G, to increase their revenues. Vilfuro-G represents the world’s first fixed-dose triple combination medication (FDC) specifically developed for the effective treatment of chronic obstructive pulmonary disease (COPD). For instance, in November 2023, Lupin Limited, an India-based pharmaceutical company, introduced Vilfuro-G. The product is provided in a fixed dose of one strength, with a recommended once-daily administration. The introduction of Vilfuro-G is anticipated to significantly improve the lives of COPD patients and broaden Lupin’s respiratory product offerings, showcasing the company’s dedication to providing cutting-edge treatment options for patients and medical professionals. Vilfuro-G is unique as the only fixed-dose combination (FDC) precisely designed to blend glycopyrronium bromide, vilanterol, and fluticasone furoate for the long-term therapy and control of moderate to severe COPD.
Which Major Firms Are Strengthening Their Position In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Major companies operating in the chronic obstructive pulmonary disease (copd) treatment market are Almirall S.A., AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A, Sunovion Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Sanofi S.A, Theravance Biopharma Inc., Verona Pharmaceuticals plc, Pfizer Inc., Mylan N.V., Orion Corporation, Cipla Limited, Glenmark Pharmaceuticals Limited, Biocon Limited, Lupin Limited, Mundipharma International Limited
Access The Complete Report For Deeper Market Insights:
Which Region Shows The Strongest Potential For Future Expansion In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2025. Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (copd) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=10054&type=smp
Browse Through More Reports Similar to the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market 2026, By The Business Research Company
Chronic Obstructive Pulmonary Disease Copd Treatment Market Report 2026
Chronic Obstructive Pulmonary Disease Copd And Asthma Devices Market Report 2026
Anti Asthmatics And Copd Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
